The Optic Neuritis Treatment Market is gaining importance as medical research improves understanding of the immune and neurological mechanisms associated with the condition. According to WiseGuyReports, the market is projected to grow from USD 500 million in 2025 to USD 1.5 billion by 2035, with a CAGR of 10.6% during 2026–2035.

The industry is seeing innovation in both therapies and delivery methods. Corticosteroids remain a central treatment category, while plasma exchange, intravenous immunoglobulin, monoclonal antibodies, and emerging biologic therapies are broadening the range of available treatment approaches.

Applications span patients with different forms and levels of disease severity. The market includes oral, intravenous, and subcutaneous treatment routes, along with diagnostic technologies such as MRI, visual evoked potential, and optical coherence tomography that help healthcare professionals evaluate optic nerve conditions.

North America is expected to remain a key market because of strong healthcare infrastructure and investment in neurological research. Europe has a well-developed treatment environment, while Asia-Pacific is expected to grow as healthcare expenditure, awareness, and access to specialized therapies increase.

Looking ahead, personalized medicine and precision diagnostics could become major areas of opportunity. AI-based imaging, telemedicine, neuroprotective therapies, and combination treatment strategies may help manufacturers and healthcare providers address the need for earlier diagnosis and more individualized care.